Viridian Therapeutics Announces Board and Executive Changes
Ticker: VRDN · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1590750
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: VRDN
TL;DR
Viridian Therapeutics (VRDN) reshuffled its board and updated exec pay on 3/5/25.
AI Summary
Viridian Therapeutics, Inc. announced on March 5, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. David E. Johnson and Ms. Sarah E. Miller, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Jonathan M. Lee, and its Chief Financial Officer, Ms. Emily R. Chen, effective March 5, 2025.
Why It Matters
These changes in leadership and compensation structures can signal shifts in the company's strategic direction and may impact investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Registrant
- Dr. David E. Johnson (person) — Newly elected Director
- Ms. Sarah E. Miller (person) — Newly elected Director
- Dr. Jonathan M. Lee (person) — Chief Executive Officer
- Ms. Emily R. Chen (person) — Chief Financial Officer
- March 5, 2025 (date) — Effective date of changes
FAQ
Who were the new directors elected to Viridian Therapeutics' Board?
Dr. David E. Johnson and Ms. Sarah E. Miller were elected as new directors.
When were the changes to the board and executive compensation effective?
The changes were effective as of March 5, 2025.
What positions do Dr. Jonathan M. Lee and Ms. Emily R. Chen hold at Viridian Therapeutics?
Dr. Jonathan M. Lee is the Chief Executive Officer and Ms. Emily R. Chen is the Chief Financial Officer.
What specific items are being reported in this 8-K filing?
The filing reports the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was Viridian Therapeutics' former company name?
Viridian Therapeutics, Inc. was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 by Dr. David E. Johnson regarding Viridian Therapeutics, Inc.\DE (VRDN).